Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-65
SponsorUniversity Hospital, Gentofte, Copenhagen

About this trial

The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabolism in healthy humans. The aim of this study is to investigate the interaction between the hormones and obtain insight into the physiology of the hormones.

The healthy participants will undergo 4 study days in a randomised order receiving the following infusions for 5 hours:

A) Amylin + PP B) Amylin + Placebo C) Placebo + PP D) Placebo + Placebo Throughout the day blood samples will be collected and gallbladder motility will be evaluated. Further, indirect calorimetry and heart rate/blood pressure measurement will be performed.

Eligibility criteria

Qualifiers

Male

Age between 18 and 65 years at the time of inclusion

Body mass index 18-27 kg/m2

Fat percentage < 20%

Disqualifiers

Anaemia (haemoglobin below normal range)

History of hepatobiliary and/or gastrointestinal disorder(s)

Kidney disease

Previous gastric or intestinal resection, cholecystectomy and/or any major intra- abdominal surgery (including bariatric surgery)

Trial design

Treatments tested in this trial

  • Amylin (Pramlintide)
  • Pancreatic Polypeptide (PP)
  • Placebo (NaCl 0.9 % solution)

Treatment groups

18 Participants
are divided into 4 treatment groups